Company intelligence / Profile preview

RMJ Partners

Not specified, Virginia, United Statesrmjpartners.com ↗

Ownership: Private
Development stage: Other

Overview

A successful Phase 2 trial of lead candidate RMJH-111b demonstrated substantial blood pressure reduction with improved safety/tolerability. The FDA has reviewed data, and a pivotal Phase 3 trial design has been agreed upon. The company uses the 505(b)(2) regulatory pathway to accelerate approval timelines by leveraging existing data on reference drugs.

Therapeutic areas: Metabolic DisordersCardiovascular
Modalities: Small moleculeMineral-based therapy (magnesium)Drug delivery technology
Industry: Biotech

Partnerships

Seeking alliance partners for commercialization/licensing but none named yet

Beyond the preview

Go deeper on RMJ Partners.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMJ Partners.

Explore the full profile